Annual report pursuant to Section 13 and 15(d)

Discontinued Operations

Discontinued Operations

12 Months Ended

Dec. 31, 2020

11.Discontinued Operations

The components of loss from discontinued operations as reported in our statements of operations were as follows:


	Years ended December 31,
	2020		2019
	(In thousands, except per share data)
Revenue:
Product revenue	$	376	$	1,006
Costs and expenses:
Cost of goods sold		1,332		1,288
Research and development		1,917		2,162
Selling, general and administrative		7,224		6,524
Total costs and expenses		10,473		9,974
Loss from discontinued operations		(10,097)		(8,968)
Other expense, net		738		—
Net loss from discontinued operations	$	10,835	$	(8,968)
Basic and diluted net loss per common share from discontinued operations	$	(2.87)	$	(11.71)
Weighted average shares used in computing basic and diluted net loss per common share		3,773		766

The following table presents information related to assets and liabilities reported as discontinued operations in our balance sheet:


	December 31,
	2020		2019
	(In thousands)
Receivables	$	—	$	555
Inventory		—		435
Prepaid expenses and other current assets		181		560
Discontinued operations – current assets	$	181	$	1,550

Accounts payable	$	1,515	$	585
Accrued clinical trials expenses		80		140
Accrued sales allowances		61		809
Other accrued liabilities		304		546
Discontinued operations – current liabilities	$	1,960	$	2,080

During both years ended December 31, 2020 and 2019 we recognized non-cash stock-based compensation expenses of approximately $0.1 million which is included in discontinued operations.